Search

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Read more

YoungEHA Webinar on Burnouts: When caregivers become patients - talking about awareness

In order to create awareness for burnout symptoms among hematologists, the YoungEHA Committee has planned a webinar on burnouts to help professionals in hematology identify early signs and how to address this issue in a wider context.

Read more

Reducing bureaucracy in clinical trials: now is the time!

Medical societies and patient advocates across disciplines have joined forces with EHA to call for urgent action to make clinical trials less bureaucratic and more patient-centered, efficient and cheaper.

Read more

Spotlight on...

We talk to leaders, thinkers and influencers to hear their thoughts on #changeOfMindset #HotInHematology to provide a #VisionOfYourFuture.

Read more

Infections in Hematology Webinar Series

Monthly webinars to provide theoretical and practical knowledge for hematologists whose patients develop infection complications. What is the Infections in Hematology Webinar Series?The series is an EHA SWG on Infections in Hematology initiative.

Read more

Congress Sponsor Program

Join us at the EHA Annual Congress, where you have the unique opportunity to connect and grow with a community of hematology experts.

Read more

Meeting report | HOPE LA 2019 | Mendoza, Argentina

The first edition of the Highlights of Past EHA (HOPE) meeting in Latin America (LA) was held on October 4-5, 2019 in Mendoza, Argentina.

Read more